Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
CNS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
Mi | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment | 288 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / July 9, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
24.06. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme and Lead Product Candidate TPI 287 | 170 | ACCESS Newswire | Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS... ► Artikel lesen | |
05.06. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit | 252 | ACCESS Newswire | In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire... ► Artikel lesen | |
16.05. | CNS Pharmaceuticals reports Q1 results | 4 | Seeking Alpha | ||
16.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update | 359 | ACCESS Newswire | Cash expected to fund operations into the second half of 2026Advancing development strategy for lead program TPI 287 to commence Phase 2 study around year end 2025 for treatment of glioblastoma multiforme... ► Artikel lesen | |
15.05. | CNS Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
13.05. | CNS Pharmaceuticals Stock Surges 36% On $5 Mln Public Offering Announcement | 1 | RTTNews | ||
13.05. | CNS Pharmaceuticals sets terms for $5 million stock offering | 3 | Investing.com | ||
13.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules | 656 | ACCESS Newswire | HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary... ► Artikel lesen | |
13.05. | Pre-market Movers: Lobo EV Technologies, CNS Pharmaceuticals, Landsea Homes, Inno Holdings, Lichen International | 547 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.25 A.M. ET).In the Green Lobo EV Technologies Ltd. (LOBO) is up over 160%... ► Artikel lesen | |
13.05. | CNS Pharmaceuticals erhält Orphan-Drug-Status für Krebsmedikament | 7 | Investing.com Deutsch | ||
13.05. | CNS Pharmaceuticals secures orphan drug status for cancer drug | 2 | Investing.com | ||
13.05. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 | 566 | ACCESS Newswire | Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM)Management... ► Artikel lesen | |
12.05. | CNS Pharmaceuticals, Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
14.04. | CNS Pharmaceuticals files to sell 5.22M shares of common stock, warrants | 1 | Seeking Alpha | ||
14.04. | CNS Pharmaceuticals, Inc. - S-1, General form for registration of securities | 2 | SEC Filings | ||
09.04. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
01.04. | CNS Pharmaceuticals reports FY results | 2 | Seeking Alpha | ||
01.04. | CNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports Full Year 2024 Financial Results | 297 | ACCESS Newswire | Company has one year of cash to fund operationsCompany advancing plans to develop TPI 287, a novel, late stage abeotaxane that is potentially blood brain barrier permeable with published clinical efficacy... ► Artikel lesen | |
31.03. | CNS Pharmaceuticals, Inc. - 8-K, Current Report | 2 | SEC Filings |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
CUREVAC | 4,620 | -0,39 % | CureVac Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
PALATIN TECHNOLOGIES | 0,116 | -11,72 % | Palatin Technologies wehrt sich gegen Delisting von der NYSE American | ||
BIOXXMED | 0,410 | 0,00 % | EQS-News: bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024 | EQS-News: bioXXmed AG
/ Schlagwort(e): Jahresbericht
bioXXmed AG informiert über die Verzögerung der Veröffentlichung des geprüften Jahresabschlusses 2024
27.06.2025 /... ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
OCUGEN | 0,950 | -1,00 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
BIO-GATE | 1,020 | 0,00 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,439 | +0,92 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
VAXART | 0,273 | -2,22 % | XFRA NB11: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILVAXART INC. DL-... ► Artikel lesen | |
BURCON NUTRASCIENCE | 1,646 | -0,60 % | Neue pflanzliche Proteinkonzepte von Lallemand, Burcon und anderen auf der IFT FIRST 2025 | ||
CELLECTAR BIOSCIENCES | 4,840 | 0,00 % | Cellectar Biosciences, Inc.: Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement | Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative... ► Artikel lesen | |
AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders' Equity Requirements | NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA... ► Artikel lesen | |
IMMUNIC | 0,686 | -0,72 % | EQS-News: Immunic AG: Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Study/Study results
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in... ► Artikel lesen | |
T2 BIOSYSTEMS | 0,086 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 20.02.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 20.02.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 20.02.2025.ISIN NameCA24703H1029 DELIVRA... ► Artikel lesen |